Nishikata M, Nomura A, Iseki K, Miyazaki K, Nakai A, Fushida H, Miyake K, Arita T
Faculty of Pharmaceutical Sciences, Mukogawa Women's University, Nishinomiya, Japan.
Eur J Clin Pharmacol. 1992;43(5):533-8. doi: 10.1007/BF02285097.
The pharmacokinetics of a single oral dose of 20 mg (+)-, (-)- and racemic homochlorcyclizine (HCZ) have been studied in humans. The formation of the quarternary ammonium-linked glucuronide was an important metabolic pathway, and the metabolic process was enantioselective as a result of differing urinary excretion rates of (+)-, (-)- and racemic glucuronide. There were significant differences between (+)-, (-)- and racemic HCZ in AUC (0-14 h) and plasma protein binding, but all HCZ enantiomers were slowly absorbed and eliminated (elimination half-lives about 11 h). The results shows help to establish a more efficient dosage regimen for HCZ therapy.
在人体中研究了单次口服20毫克(+)-、(-)-和消旋高氯环嗪(HCZ)的药代动力学。季铵连接的葡萄糖醛酸苷的形成是一条重要的代谢途径,由于(+)-、(-)-和消旋葡萄糖醛酸苷的尿排泄率不同,代谢过程具有对映体选择性。(+)-、(-)-和消旋HCZ在AUC(0 - 14小时)和血浆蛋白结合方面存在显著差异,但所有HCZ对映体吸收和消除缓慢(消除半衰期约11小时)。这些结果有助于建立更有效的HCZ治疗给药方案。